Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers: A systematic review and meta-analysis of randomized controlled trials
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0307800 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, 2024. Verfasst von Fitriyadi Kusuma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology Gynecology, Department of Obstetrics and Gynecology, Dr. Cipto Mangunkusumo Hospital, Greater Jakarta, Daerah Khusus Ibukota Jak…. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, Immune Checkpoint Inhibitors, Randomized Controlled Trials as Topic, Patient Reported Outcome Measures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Over the past decades, immune checkpoint inhibitors (ICIs) have shown dramatic efficacy in improving survival rates in multiple malignancies. Recently, gynecological cancer patients also showed to respond favorably to ICI treatment. This study aimed to evaluate the efficacy, safety, and patient-reported outcomes of ICI therapy in gynecological cancers. We conducted a systematic review and meta-analysis by retrieving literature from multiple electronic databases, such as MEDLINE, ScienceDirect, EBSCO, ProQuest, and Google Scholar. The protocol used in this study has been registered in PROSPERO (CRD42022369529). We included a total of 12 trials involving 8 therapies and 8,034 patients. ICI group demonstrated a longer OS (HR: 0.807; 95% CI: 0.719, 0.907; p = 0.000) and greater PFS improvement (HR: 0.809; 95% CI: 0.673, 0.973; p = 0.024) compared to the control group. There was no significant difference in the incidence of treatment-related adverse events [RR: 0.968; 95%CI: 0.936, 1.001; p = 0.061], but a higher incidence of immune-related adverse events (IRAEs) was observed in the ICI group (RR: 3.093; 95%CI: 1.933, 4.798; p = 0.000). Although the mean changes of QOL score from baseline was not significantly different between both groups (SMD: 0.048; 95% CI: -0.106, 0.202; p = 0.542), the time to definitive QOL deterioration was longer in the ICI group (HR: 0.508; 95% CI: 0.461, 0.560; p = 0.000). Despite having a higher incidence of IRAE, ICI was shown to improve survival rates and QOL of patients. Thus, it should be considered as a new standard of care for gynecologic cancers, especially in advanced stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Oncology Gynecology, Department of Obstetrics and Gynecology, Dr. Cipto Mangunkusumo Hospital, Greater Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia.
- School of Medicine and Health Sciences, Department of Medicine, Atma Jaya Catholic University of Indonesia, North Jakarta, Daerah Khusus Ibukota Jakarta, Indonesia.
- Lewoleba General Hospital, Lembata Island, East Nusa Tenggara, Indonesia.
ORCID-Profile: Glenardi Glenardi, Ghea Mangkuliguna, Hariyono Winarto
Zitieren
APA
Kusuma, F., Glenardi, G., Mangkuliguna, G., Winarto, H., Purwoto, G., Utami, T. W., & Anggraeni, T. D. (2024). Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers: A systematic review and meta-analysis of randomized controlled trials. PLOS ONE. https://doi.org/10.1371/journal.pone.0307800
Vancouver
Kusuma F, Glenardi G, Mangkuliguna G, Winarto H, Purwoto G, Utami TW, et al. Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers: A systematic review and meta-analysis of randomized controlled trials. PLOS ONE. 2024. doi:10.1371/journal.pone.0307800
BibTeX
@article{Kusuma2024,
author = {Kusuma, Fitriyadi and Glenardi, Glenardi and Mangkuliguna, Ghea and Winarto, Hariyono and Purwoto, Gatot and Utami, Tofan Widya and Anggraeni, Tricia Dewi},
title = {Efficacy, safety, and patient-reported outcome of immune checkpoint inhibitor in gynecologic cancers: A systematic review and meta-analysis of randomized controlled trials},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0307800}
}
EUVIMED